stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Price to free cash flow
AbCellera Biologics Inc. has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,056× (February 2021) — the current reading is the lowest in ten years.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 13.2× | (37.62%) |
| FY2021 | 21.2× | (97.35%) |
| FY2020 | 799× | 5.82% |
| FY2019 | 755× | 0.00% |
| FY2018 | 755× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| ABCL AbCellera Biologics Inc. | n/m |
| IOVA Iovance Biotherapeutics, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| ARQT Arcutis Biotherapeutics, Inc. compare | 74.9× |
| Biotechnology industry median | 25.2× |
| Healthcare sector median | 20.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement